Don't Miss

Identifying new orphan drug opportunity

With year-on-year growth outstripping that of the pharmaceutical market as a whole, sales of orphan drugs are forecast to rise to $217 billion by 2024 and could account for 18% of total prescription drug sales. The orphan drugs sector presents investors, big pharma and biotech companies with significant commercial benefits. With major brands such as Merck's Keytruda and Bristol Myers Squibb's Revlimid and Opdivo demonstrating the potential, stakeholders must carefully scan the future orphan drug development landscape to identify the next opportunities. Fully updated and expanded, , The Orphan Drug Fact File 2020 is a comprehensive, independent analysis that will provide a complete assessment of orphan drug research activity. Find out more >>

Insight, Analysis and Views

BMS gets EU panel backing for CAR-T therapy Breyanzi

My News

Upgrade your subscription to get more features!

Conference News

Latest News